Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Lonasen Patch Hits PIII Primary Target in Japan, Filing Planned in 1st Half of FY2018: Sumitomo Dainippon, Nitto Denko
February 15, 2018
- New Dosage Strength Approved for Enbrel Pen: Pfizer
February 14, 2018
- Adcetris Filed in Japan for Frontline Hodgkin’s Lymphoma: Takeda
February 14, 2018
- Zytiga Shows Consistent Efficacy in Japanese High-Risk mHNPC Patients
February 14, 2018
- New IITs for Oncolytic Virus to Begin for Head and Neck Cancer, Sarcoma: Oncolys
February 13, 2018
- Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
February 13, 2018
- 2018 to See Transition to “Leap Phase” in Kyowa Kirin’s Midterm Plan: President
February 13, 2018
- Hiroshima Couple Arrested for Counterfeit Harvoni Case
February 9, 2018
- Nipro Grabs Rights to TC BioPharm’s CAR-T Therapy
February 9, 2018
- Kyowa Kirin Logs Higher Earnings on Milestones, Lower R&D Costs
February 9, 2018
- Ethical Drug Sales Up 2.1% in December on Cancer Meds, SGLT2
February 9, 2018
- Hisamitsu to Form Hong Kong Subsidiary to Step Up Salonpas, Mohrus Sales
February 9, 2018
- Otsuka Ups 2017 Profit Estimate on US Tax Reform
February 9, 2018
- Positive RA Data Out for JAK Inhibitor Peficitinib, Astellas Gears Up for Filing
February 9, 2018
- Fujifilm, Takeda Strike Deal on iPS Cell-Based Heart Therapy
February 9, 2018
- YL Biologics’ Enbrel Biosimilar Shows Equivalent Efficacy to Originator
February 8, 2018
- Daiichi Sankyo’s ADC U3-1402 Enters PI Study in US for NSCLC, Eyeing Its Multinational Study
February 8, 2018
- Torii Enjoys Earnings Rise on New HIV Drugs
February 7, 2018
- Xtandi Cuts Risk of Metastasis or Deaths by 71% in Non-Metastatic CRPC
February 7, 2018
- EA Pharma Launches Rectabul, Boosts Efforts on Humira to Gird for IBD Showdown
February 7, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…